The Development and Reform Commission of Beijing and other departments have issued the "Action Plan for Accelerating the Innovative Development of the Synthetic Biology Manufacturing Industry in Beijing". By 2026, Beijing's synthetic biology manufacturing will achieve a comprehensive improvement in the gathering of innovative resources, the source of industrial innovation, the leading role of demonstration applications, and the driving force of regional radiation, forming a basic development pattern of sourcing innovation in Beijing, supporting Hebei and radiation nationwide.

Landing a batch of innovative products in key application areas, adding 3 synthetic biology manufacturing listed companies, fostering 5-10 leading companies with domestic and international influence, nurturing more than 100 excellent start-up hard-tech companies, and preliminarily forming 1-2 billion-level industrial agglomeration areas.

Support the construction of common technology platforms, provide common technology research and development and application services for industrial needs, and provide support of up to 50 million yuan. For professional pilot platform construction projects with distinctive layout and prominent advantages, fixed asset investment will be subsidized based on no more than 30% of the total project investment, up to a maximum of 50 million yuan.

Support qualified leading companies, universities, research institutions, and small and medium-sized enterprises in the upstream and downstream of the industrial chain to form innovation consortia, establish synthetic biology manufacturing technology innovation centers, and provide support of up to 30% of the construction budget, with a total support amount of no more than 50 million yuan per individual technology innovation center.

By 2026, Beijing will produce a number of major original achievements, break through a number of core key technologies urgently needed by industries, nurture no less than 5 leading synthetic biology teams, and build a source of original innovation in synthetic biology manufacturing with international influence. Establish a microbial strain preservation library with a capacity of over 0.1 million strains, add approximately 0.01 million strains of patented preserved strains, and establish no less than 2 synthetic biology manufacturing design and automatic control platforms, and 3-5 thousand-liter-scale pilot-scale process amplification platforms.

Landing a batch of innovative products in key application areas, adding 3 synthetic biology manufacturing listed companies, fostering 5-10 leading companies with domestic and international influence, nurturing more than 100 excellent start-up hard-tech companies, and preliminarily forming 1-2 billion-level industrial agglomeration areas.

West Securities said that synthetic biology is still in the early stage of industrialization, and Chinese companies are expected to become globally competitive enterprises with synthetic biological products and cost advantages. It is recommended to pay attention to the direction of cost leadership or high value-added products and strong industrialization. Huatai Securities stated that bioprocessing is the main production process for amino acids, and currently the amino acid sector is one of the sectors leading the realization of performance in the field of synthetic biology. It is bullish on the development and valuation reshaping of the amino acid industry driven by the progress of synthetic biology technology.

Concept companies related to synthetic biology:

Fufeng Group (00546): It is an international bio-fermentation product company mainly engaged in the research, production, and operation of various amino acids and their derivative products and bio-colloids. It is a globally famous producer of monosodium glutamate, xanthan gum, and amino acids. Fufeng Group recently released its full-year performance for 2023, with revenue of approximately 28 billion yuan, a year-on-year increase of 1.9%; shareholders' attributable profit of approximately 3.1 billion yuan, a year-on-year decrease of 18.6%; earnings per share of 124.02 cents.

Juzi Biological (02367): It is a biotechnology company rooted in scientific aesthetics and a pioneer and leader in the professional skincare products industry in China based on bioactive ingredients. The company uses proprietary synthetic biology technology to design, develop, and produce bioactive ingredients such as recombinant collagen and rare ginsenosides, focusing on three major industrial directions: functional skincare products, medical instruments, functional foods, and special medical purpose formula foods.